![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
| Anticuerpo monoclonal en estudio para el tratamiento de algunos tipos de cáncer. Los anticuerpos monoclonales se producen en el laboratorio y pueden localizar sustancias del cuerpo y unirse a ellas, incluso a las células cancerosas. El anticuerpo monoclonal anti mesotelina MORAb-009 se une a la mesotelina (una proteína elaborada por algunas células cancerosas) e impide que las células se multipliquen. También se llama MORAb-009. |
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081011025907im_/http://www.nci.nih.gov/images/spacer.gif) |